November 2008 Volume 4, Issue 11
Volume 4, Issue 11 | November 2008
November 2008
In this Issue
Global News
Focus on emerging markets
GSK snags Egyptian mature products business of Bristol-Myers Squibb for $210 millionComing in from the cold
Lipoxen, Cambridge Biostability work to develop improved vaccines that are stable at ambient temperaturesPfizer, UCB announce joint venture
New company Cyclofluidic aims to accelerate drug discovery via automating flow chemistry, flow biologyTheratechnologies, EMD Serono in HIV tesamorelin licensing deal
Theratechnologies Inc. and EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced the companies entered a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy.Pfizer to settle Bextra and Celebrex lawsuits for $894 million
Settlement to resolve personal injury and class action lawsuits, state AG claimsEditor's Focus
Economic meltdown and where the money is
It’s pretty hard to be the editor of a business publication and not address the recent world-wide economic meltdown. What’s to make of this mess, and what are the potential impacts on the biotech and pharmaceutical industry?Commentary
Now what do we do? Challenges abound in life sciences for new graduates and experienced alike
Twenty years ago, life in Big Pharma was genteel and secure. Today, it is neither. There are always good career opportunities for the best, and the only way to be the best is to get to work and not wait for miracles.A solid team in the life sciences
Just as our editorial staff delivers the news to our readers, our sales staff delivers integrated marketing opportunities to the advertising community. DDN is very fortunate that in our fourth year, we have a veteran sales team, all of whom have deep and significant experience in life science publishing, to help our advertisers design their own customized integrated marketing programs.Informatics
Bringing down Big Pharma's fortress
SIMDAT Project ends with successful virtual outsourcing project at GSKEarly warning system
CSS Informatics, DrugLogic integrate safety data technologies to allow early detection of adverse trial eventsIn-depth in silico discovery
Life Biosystems, Temis solution offers analysis of large-scale bibliographic informationGunning for genomics
Integromics, Tibco roll out genomics data analysis solutionMaking massive models
Biogen Idec to process inflammatory disease data using Gene Network Sciences' REFS softwareAutomation & Instrumentation
A perfect deal from A to Z
Advalytix to private-label ZyGEM's temperature-controlled extraction technologySpeeding up ADME
BD Biosciences, BioTrove to provide a solution from sample prep to data analysisRadiolabeling for ADME
PerkinElmer launches GMP radiolabeling servicesInvitrogen hepatocytes pair with Qualyst’s B-Clear
In a move that should markedly enhance the market opportunities for Qualyst’s B-Clear hepatocyte research kits and contract services, the company has agreed with Invitrogen to offer hepatocyte screening services and research products through the latter’s wholly-owned subsidiary, CellzDirect.Feature
Lighting up in vitro and in vivo work
Imaging technologies, particularly luminescent ones, are increasingly important to discovery/developmentResearch & Development
Cooperating for a worthy cause
Eli Lilly, Merck and IDRI tackle global threat of TBA partner's partnership
Ligand's acquisition of Pharmacopeia to focus on Big Pharma partnershipsEasier way to make stem cells
Harvard researchers use chemicals in place of two cancer genes in reprogramming processLate-stage letdown
Cell Genesys axes 75 percent of staff after cancelling VITAL-1 Phase III trialsBetter late than never
ARCA biopharma, Nuvelo merger creates late-stage cardiovascular biotechGenomics & Proteomics
Getting in touch with our inner germs
NIH kicks off the Human Microbiome Project with first awardsSlashing genome prices
Complete Genomics promises $5,000 human whole-genome sequencing by next yearGiving RNAi some lip service
RXi Pharma obtains exclusive worldwide license to technology for the oral RNAi delivery
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
The unsung tools behind analytical testing success
Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
Improving ALS research with pluripotent stem cell-derived models
Discover new advancements in modeling amyotrophic lateral sclerosis.
Automating 3D cell selection
Discover precise automated tools for organoid and spheroid handling.
